Adverum Biotechnologies Inc

NASDAQ:ADVM  
1.56
+0.02 (+1.30%)
Debt Financing / Related

Adverum Biotechnologies Inc Finalizing Two-Dose Study Design For Phase 2 Trial Of ADVM-022 In Wet Amdwith Intention To Dose First Patient In Q32022

Published: 12/21/2021 13:15 GMT
Adverum Biotechnologies Inc (ADVM) - Adverum Biotechnologies Inc - Finalizing Two-dose Study Design for Phase 2 Trial of Advm-022 in Wet Amdwith Intention to Dose First Patient in Q32022.
Adverum Biotechnologies Inc - Anticipates Near-term Hires to Further Strengthen Executive Team.
Adverum Biotechnologies Inc - Expects Cash Position to Fund Development Plans and Operations Into 2024.
Adverum Biotechnologies - Intends to File Ind Amendment in H1 of 2022, Engage With FDA With Aim of Securing Agreement on Phase 2 Trial Design.
Adverum Biotechnologies Inc - Plan to Dose First Patient in Phase 2 Trial of Advm-022 in Wet Amd in Third Quarter 2022.